NL-OMON36216已完成2 期
Individualized Dose Escalation for non-small cell Lung cancer (NSCLC) using volumetric modulated arc therapy (VMAT) - IDEAL-VMAT for NSCLC
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histologically or cytologically confirmed stage IIIA/B NSCLC (excluding pleural effusion or mixed pathology)
- •2. Irresectable disease (as assessed by multidisciplinary team) or patient refusing surgery
- •3. Disease which can be encompassed within a radical radiotherapy treatment plan in keeping with standard practice at the participating center
- •4. Proposed treatment consists of radiotherapy alone, induction chemotherapy followed by radiotherapy, or concurrent chemoradiation
- •5. WHO performance status 0 or 1
- •6. Adequate respiratory function: FEV1 * 1.5 L and DLCO > 40%, predicted on baseline pulmonary function tests
- •7. Age * 18 years, no upper age limit
- •8. Estimated life expectancy of more than 6 months
- •9. Patient is available for follow-up
- •10. Written informed consent obtained
排除标准
- •1. Clinically diagnosed NSCLC
- •2. Previous or current malignant disease likely to interfere with the protocol treatment or comparisons
- •3. Prior thoracic radiotherapy
- •4. Prior lobectomy / pneumonectomy
- •5. Prior chemotherapy using gemcitabine or bleomycine
- •6. Superior sulcus tumors if the brachial plexus is within the high-dose volume
- •7. Medically unstable (e.g., ischaemic heart disease, esophageal disorders)
- •8. Pregnancy
- •9. Connective tissue disorders
- •10. Inability to comply with protocol or trial procedures
研究者
相似试验
终止
2 期
Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)RadiotherapyStage III Non-small Cell Lung CancerIndividualized Radiation Dose EscalationNCT01577212Radboud University Medical Center6
进行中（未招募）
1 期
A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy resistant ovarian or lung cancer.Platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC)CTIS2024-511074-80-01Tubulis GmbH140
尚未招募
不适用
A first-in-human dose escalation and expansion study with the SIRPa-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin*s Lymphoma (NHL)NHSlymphomaNL-OMON56086Byondis Bv.8
尚未招募
1 期
A First-in-Human Study to Evaluate the Administration of ReoCure alone and in combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid TumoursAdvanced Malignant Solid TumoursCancer - Any cancerACTRN12620000777998ViroCure, Inc.45
进行中（未招募）
1 期
recurrent advanced ovarian cancerEUCTR2013-002755-15-BEGanymed Pharmaceuticals AG99